Percutaneous transluminal angioplasty is frequently used in patients with severe arterial narrowing due to atherosclerosis. However, it induces severe arterial injury and an inflammatory response leading to restenosis. Here, we studied a potential activation of the endocannabinoid system and the effect of fatty acid amide hydrolase (FAAH) deficiency, the major enzyme responsible for endocannabinoid anandamide degradation, in arterial injury. We performed carotid balloon injury in atherosclerosisprone apolipoprotein E knockout (ApoE 
INTRODUCTION
Catheter-based balloon dilatation of stenotic arteries is a frequent intervention in patients with coronary or peripheral artery disease (1, 2) . Despite its beneficial effects in improving the blood flow it leads to vascular injury, loss of endothelium and subsequent platelet deposition (3) . Together with leukocytes that are recruited to the site of vascular injury in response to chemokine release (4), platelets synthesize growth factors and proinflammatory cytokines (3) . Vascular injury also induces medial SMC apoptosis and subsequent proliferation of neighboring SMCs, followed by migration of a subpopulation of medial SMCs into the intima in response to platelet-derived growth factor (PDGF) or other stimuli (5) . Intimal SMCs further proliferate and undergo phenotypic changes (6) . Current therapeutic strategies to block vascular SMC proliferation are based on drug-eluting stents releasing antiproliferative agents such as sirolimus or paclitaxel. However, a major complication of these drug-eluting stents is delayed endothelial healing and in stent-thrombosis, due to inhibitory effects of these drugs on the reendothelialization process and prothrombotic properties (7) (8) (9) .
In recent years the endocannabinoid system, an endogenous lipid signaling system, has gained interest as potential therapeutic target for various disorders including cardiovascular disease (10) . The classical cannabinoid receptors CB 1 and CB 2 belong to the family of seven trans-membrane G-protein coupled receptors. They are part of the endocannabinoid system, which further comprises endogenous ligands (endocannabinoids) and enzymes implicated in synthesis and metabolism of endocannabinoids. One of the key enzymes is FAAH, responsible for the degradation of the endocannabinoid anandamide (11) . Anandamide binds marginally more readily to CB 1 than to CB 2 receptors and exhibits lower CB 2 than CB 1 efficacy (12) . In by guest, on October 22, 2017 www.jlr.org Downloaded from addition, FAAH is also partly responsible for the metabolism of other Nacylethanolamines, i.e. palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), which activate peroxisome proliferator-activated receptor-α (PPAR-α) (13, 14) .
Within the vascular system, CB 1 and CB 2 are expressed on endothelial and smooth muscle cells as well as immune cells (10) . In vitro studies demonstrated that both CB 1 and CB 2 affect vascular SMC proliferation and migration. In particular, activation of CB 2 with synthetic ligands or blockade of CB 1 signaling was found to inhibit SMC inflammatory responses (15, 16) . In support of a potential relevance for restenosis prevention, we found that in vivo administration of CB 2 agonists reduced neointima formation in a mouse model of balloon injury (17) . The underlying mechanisms of CB 2 -mediated protection involved inhibitory effects on macrophage and SMC inflammatory responses. The in vivo role of CB 1 and potential elevation of endocannabinoid levels in restenosis has not been investigated so far. A major limitation for in vivo studies of endocannabinoid effects is their rapid metabolism. To overcome this problem, mice lacking the major anandamide degrading enzyme FAAH have been developed. These mice have strongly increased anandamide levels, in particular in brain and liver, confirming the key role of FAAH in anandamide degradation (11, 18) . We recently demonstrated that FAAH deficiency in atherosclerosis-prone mice leads to the development of an unstable atherosclerotic plaque phenotype due to enhanced neutrophil recruitment (19) .
In the present study, we focused on the role of endocannabinoid signaling in restenosis. In particular, we investigated a potential activation of the endocannabinoid system in response to balloon-induced arterial injury. We further studied the consequence of enhanced anandamide levels in FAAH-deficient mice as well as of pharmacological CB 1 blockade on neointima formation. Data acquisition and analysis were performed using Analyst software version 1.5.1
MATERIALS AND METHODS

Mouse model of balloon-induced arterial injury
(AB Sciex, ON, Canada) (21) .
Blood analysis
For measurements of differential blood cell counts (hematocytometer; Sysmex Digitana AG) and serum endocannabinoid and cholesterol content, blood samples were collected at endpoints by cardiac puncture.
Cholesterol measurement
Three pools of serum (from two mice per pool) were used per group of mice. In each pool, total cholesterol concentration was measured using an enzymatic colorimetric assay (BioMérieux, France). Then, lipoproteins were separated by fast protein liquid Quantifications were performed by computer image analysis using MetaMorph6 software (Zeiss).
Smooth muscle cell isolation and proliferation
Primary vascular smooth muscle cells from thoracoabdominal aortas of ApoE 
Statistical analysis
All results are expressed as mean (±SEM 
RESULTS
Balloon injury increases systemic endocannabinoid levels and arterial CB 1 expression
We tested a potential activation of the endocannabinoid system in response to balloon-induced arterial injury and found systemically elevated endocannabinoid anandamide levels in ApoE -/-mice 7 days after balloon injury ( Figure 1A, P<0.005) . 
Genetic deficiency of anandamide metabolizing enzyme FAAH increases neointima formation
In order to clarify the causal effect of increased systemic anandamide levels in response to arterial injury, we investigated the effect of anandamide-degrading enzyme FAAH deficiency on neointima formation. At baseline, ApoE Figure 4A-B) . In both groups, the lumen area significantly decreased from 7 to 28 days due to neointimal thickening ( Figure 4C ). However, the reduction of lumen area was lower in mice treated with the CB 1 antagonist (Figure 4C , P<0.05). In both groups the EEL circumference slightly increased from 7 to 28 days post-injury due to outward remodeling. (Figure 4D , P<0.05). We further determined which cell type was affected by the protective effects of CB 1 antagonism. We found a non-significant tendency for decreased CD68-positive macrophage content ( Figure 4E ), while SMC content determined by α-SMA staining was significantly reduced in AM281-treated mice ( Figure 4F , P<0.05). To verify that CB 1 antagonism with AM281 did not affect endothelial repair, we performed immunostaining of the endothelial cell marker platelet endothelial cell adhesion molecule 1 (CD31). In both vehicle and AM281-treated mice, complete reendothelialization was observed after 7 days ( Figure 4G ).
CB 1 deficiency or antagonism inhibits BMDM adhesion and migration as well as SMC proliferation
To strengthen our in vivo findings suggesting that SMCs rather than macrophages are the major cell type affected by CB 1 antagonism, we performed a set of in vitro experiments. We therefore isolated macrophages from the bone marrow and smooth muscle cells from aortas of CB neutrophil-derived granule proteins were shown to play a protective role by promoting reendothelialization (28) .
As opposed to potential effects on immune cells, our data suggest that the protective effect of CB 1 antagonism on neointima formation is largely attributable to inhibition of SMC proliferation. This is in agreement with previous in vitro data reporting decreased proliferation and migration of PDGF-stimulated human coronary artery SMCs in response to the CB 1 antagonist rimonabant (16). In this study, rimonabant was found to attenuate intracellular Ras and ERK1/2 signaling pathways.
To exclude the possibility of non-specific effects in response to pharmacological CB 1 blockade, we confirmed the role of CB 1 in SMC proliferation by using CB 1 -/-SMCs.
Remarkably, we observed a functional effect in isolated CB 1 -/-and FAAH threatening complication, has emerged as a major safety concern (29) (30) (31) . In fact, a key player in the pathogenesis of late stent thrombosis is delayed healing, characterized by persistent fibrin deposition and the lack of complete endothelial repair (32) . Thus, the development of novel strategies to prevent restenosis without impairing the arterial healing process is of crucial importance.
In conclusion, endocannabinoid signaling through CB 1 receptors plays a detrimental role in neointima formation by stimulating SMC proliferation, suggesting a potential therapeutic benefit of CB 1 receptor blockade.
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